论文部分内容阅读
目的探讨在乳腺癌新辅助治疗中多西他赛和表柔比星联用时的用药顺序对化疗效果的影响。方法回顾性分析2010—2014年我院先使用表柔比星再使用多西他赛(对照组,34例)及先使用多西他赛后使用表柔比星(观察组,58例)的乳腺癌病历,评价行3个疗程后的近期疗效。结果对照组近期有效率61.76%,生存获益85.29%;观察组近期有效率74.13%,生存获益91.37%。结论临床在乳腺癌的新辅助治疗过程中,宜采用先使用紫杉烷类药物后使用蒽环类药物的给药次序。
Objective To investigate the effect of docetaxel combined with epirubicin on neoadjuvant chemotherapy in breast cancer. Methods Retrospective analysis of docetaxel (34 in control group) and epirubicin (58 in observation group) before using docetaxel in our hospital from 2010 to 2014 Breast cancer records, evaluation of the line after 3 courses of immediate effect. Results In the control group, the effective rate was 61.76%, and the survival benefit was 85.29%. The observation group had an effective rate of 74.13% and a survival benefit of 91.37%. Conclusion In the course of neoadjuvant therapy of breast cancer, the order of administration of anthracyclines after the first use of taxanes should be adopted.